Literature DB >> 16942536

Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside.

C Charles Wen1, Ricardo Munarriz2, Iain McAuley3, Irwin Goldstein2, Abdulmaged Traish4, Noel Kim5.   

Abstract

INTRODUCTION: Ischemic priapism is associated with cavernosal acidosis, which decreases the efficacy of adrenergic agonists. We determined the effect of acidosis on ligand dissociation from adrenergic receptors and assessed the efficacy of high-dose phenylephrine in treating patients with acute ischemic priapism.
METHODS: Dissociation rates of [3H]prazosin were determined at pH 7.2 and 6.9 in membrane preparations of rabbit penile cavernosal tissue. Vital signs were recorded from patients before injection, and at 1 minute and 5 minutes after injection of high-dose phenylephrine (1,000 mg q 5 minutes) for 17 consecutive cases of iatrogenic ischemic priapism that occurred after vascular assessment. We also provide two case reports of prolonged ischemic priapism successfully managed with high-dose phenylephrine.
RESULTS: Dissociation rates of [3H]prazosin were greater at pH 6.9 (K (-1) = 0.23/minute) than at pH 7.2 (K (-1) = 0.10/minute), suggesting decreased receptor affinity at acidic pH. Intracavernosal therapy with high-dose phenylephrine (mean dose 2,059 +/- 807 microg) was 100% effective with no adverse events or significant changes in vital signs. In addition, two patients with ischemic priapism for > or =36 hours were successfully treated with high-dose intracavernosal phenylephrine (mean dose 45,000 microg) without any adverse event. Both patients are currently potent.
CONCLUSIONS: Acidic pH may decrease the binding affinity of adrenergic ligands to their receptors. Phenylephrine at doses higher than previously reported may be necessary to overcome this decreased affinity in acidosis associated with ischemic priapism. High-dose intracavernosal phenylephrine administration is safe and effective in the management of ischemic priapism. Continuous cardiovascular monitoring is advised.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942536     DOI: 10.1111/j.1743-6109.2005.00140.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  12 in total

Review 1.  Recent advances in the medical and surgical treatment of priapism.

Authors:  Adam Shrewsberry; Aaron Weiss; Chad W M Ritenour
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

Review 2.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

3.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

4.  A Case Report of Hypertensive Emergency and Intracranial Hemorrhage Due to Intracavernosal Phenylephrine.

Authors:  Raga Deepak Reddy Palagiri; Kshitij Chatterjee; Anusha Jillella; Drayton A Hammond
Journal:  Hosp Pharm       Date:  2018-05-29

5.  [Diagnosis and management of priapism].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

Review 6.  Prophylactic phenylephrine for iatrogenic priapism: a pilot study with Peyronie's patients.

Authors:  Pengbo Jiang; Athena Christakos; Mina Fam; Hossein Sadeghi-Nejad
Journal:  Korean J Urol       Date:  2014-10-10

Review 7.  Review of Ischemic and Non-ischemic Priapism.

Authors:  Mark G Biebel; Martin S Gross; Ricardo Munarriz
Journal:  Curr Urol Rep       Date:  2022-05-10       Impact factor: 3.092

Review 8.  Priapism: current updates in clinical management.

Authors:  Phil Hyun Song; Ki Hak Moon
Journal:  Korean J Urol       Date:  2013-12-10

9.  Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism.

Authors:  Jiaming Wen; Xianzhen Jiang; Yingbo Dai; Yujin Zhang; Yuxin Tang; Hong Sun; Tiejuan Mi; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  J Sex Med       Date:  2010-09       Impact factor: 3.802

10.  Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies.

Authors:  Genevieve M Crane; Nelson E Bennett
Journal:  Anemia       Date:  2010-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.